CytRx Reports 2013 First Quarter Financial Results

CytRx Reports 2013 First Quarter Financial Results

(NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended March 31, 2013.

“We are focusing on advancing the clinical development of aldoxorubicin for the treatment of patients with soft tissue sarcoma as well as for various other indications, and expanding our oncology pipeline by combining our novel linker platform technology with additional chemotherapeutic agents,” said Steven A. Kriegsman, CytRx President and CEO. “Our linker technology has proven affinity to attach to multiple chemotherapeutic agents, opening the potential for its use in treating a majority of solid tumors and cancers of the blood. We can concentrate additional financial resources toward this focus following our previously announced decision to terminate development of tamibarotene.”

Net loss for the three months ended March 31, 2013 was $6.9 million, or $0.23 per share, compared with a net loss of $10.1 million, or $0.49 per share, for the three months ended March 31, 2012. In the first quarters of 2013 and 2012, the Company recognized non-cash losses of $2.1 million and $3.9 million, respectively, on the valuation of warrant derivative liabilities related to warrants issued in August 2011 and July 2009.The Company did not recognize revenues for the first quarters of 2013 and 2012.

Research and development (R&D) expenses were $3.2 million for the first quarter of 2013, and included development expenses of $1.6 million for aldoxorubicin and $0.9 million for tamibarotene. R&D expenses were $4.4 million for the first quarter of 2012.

General and administrative (G&A) expenses were $1.8 million for the first quarter of 2013, compared with $1.9 million for the first quarter of 2012. G&A expenses included non-cash stock-compensation expense of $0.2 million for each of the respective quarters ended March 31, 2013 and 2012.

CytRx reported cash, cash equivalents and short-term investments of $32.4 million as of March 31, 2013.

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline is focused on the clinical development of its tumor-targeting doxorubicin conjugate (formerly known as INNO-206). CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and has initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. The Company is initiating a Phase 3 pivotal trial under a special protocol assessment (SPA) with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx is expanding its pipeline of oncology candidates based on its proprietary linker platform technology that can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib. The Company completed its evaluation of in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib, and is evaluating further development of tamibarotene. For more information about CytRx Corporation, visit .

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx's clinical trials, the risk that any future human testing of aldoxorubicin, the Company’s linker technology and other drug candidates might not produce results similar to those seen in past human or animal testing, risks related to CytRx's ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx's need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 3 clinical development of aldoxorubicin, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.